BeiGene, Zai Lab Look To Clear US Delisting Uncertainties
US Exit A Viable Option?
Executive Summary
US-listed Chinese biotechs are switching auditors in hopes of satisfying the US securities regulator's demands - but legal experts also see other considerations at play.
You may also be interested in...
Delisting Looms As More US-Listed China Companies Seek To Move Closer Home
After five state-owned US-listed Chinese firms announce plans to delist from the US stock market, private firms such as Alibaba follow the lead.
China Closes In On Top 10 In Global Innovation Ranking
China is knocking on the door of the world’s top 10 most innovative economies, helped by sustained investment.
China Drug Price Negotiations: Another Race To The Bottom？
With the fourth quarter just around the corner, China's closely-watched annual drug reimbursement and prices negotiations are entering a key final stage. But will applicants need to be more strategic than expedient?